SBIR Phase I: Genetically Engineered Dendritic Cell to Activate SARS-CoV-2 Spike Protein s — NSF Award to NEYROBLASTGX LLC (CA, $2
The broader impact /commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop a specific immunoprotective cell therapy using the SARS-CoV-2 spike protein (Sp) to boost immunity against COVID-19, especially with comorbidities. A durable competitive advantage reflects immune cel
| Award title | SBIR Phase I: Genetically Engineered Dendritic Cell to Activate SARS-CoV-2 Spike Protein s |
|---|---|
| Award ID | 2051522 |
| Awardee | NEYROBLASTGX LLC |
| City | MURRIETA |
| State | CA |
| Amount obligated | $255,997 |
| Principal investigator | Aynun Begum |
| Program | SBIR Phase I |
| Start date | 04/01/2021 |
| Abstract | The broader impact /commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop a specific immunoprotective cell therapy using the SARS-CoV-2 spike protein (Sp) to boost immunity against COVID-19, especially with comorbidities. A durable competitive advantage reflects immune cell engineering with novel coronavirus Sp as a new technological advancement for stem cell-based immunotherapy (SCT) to treat viral diseases, diabetes, autoimmune disorders, or cance |
| Source | NSF Awards |
$799/mo
Try NSFGrants →